Journal of medical economics
-
Randomized Controlled Trial Multicenter Study Comparative Study
The costs of treating acute heart failure: an economic analysis of the SURVIVE trial.
To estimate the incremental cost per life year gained with levosimendan relative to dobutamine in treatment of acute heart failure based on the Survival of Patients with Acute Heart Failure in Need of Intravenous Inotropic Support (SURVIVE) trial. ⋯ At an acquisition cost of euro600 per vial, there is at least 50% likelihood that levosimendan is cost effective relative to dobutamine if willingness to pay is equal to or greater than euro15,000 per life year gained.